Prevalence estimates of tuberculosis infection in adults in Denmark: a retrospective nationwide register-based cross-sectional study, 2010 to 2018
Authors:
- Anne Ahrens ØstergaardAØAnne Ahrens Østergaard
- Troels LillebaekTLTroels Lillebaek
- Inge PetersenIPInge Petersen
- Andreas FløeAFAndreas Fløe
- Ole HilbergOHOle Hilberg
- Inge K HoldenIHInge K Holden
- Lone LarsenLLLone Larsen
- Ada ColicACAda Colic
- Christian WejseChristian Wejse
- Pernille RavnPRPernille Ravn
- Bente Mertz NørgårdBNBente Mertz Nørgård
Open Access
- 21 March 2024
- journal article
- research article
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (12) , 2300590
Abstract
Background: Tuberculosis (TB) elimination requires identifying and treating persons with TB infection (TBI). Aim: We estimate the prevalence of positive interferon gamma release assay (IGRA) tests (including TB) and TBI (excluding TB) in Denmark based on TBI screening data from patients with inflammatory bowel disease (IBD) or inflammatory rheumatic disease (IRD). Methods: Using nationwide Danish registries, we included all patients with IBD or IRD with an IGRA test performed between 2010 and 2018. We estimated the prevalence of TBI and positive IGRA with 95% confidence intervals (CI) in adolescents and adults aged 15–64 years after sample weighting adjusting for distortions in the sample from the background population of Denmark for sex, age group and TB incidence rates (IR) in country of birth. Results: In 13,574 patients with IBD or IRD, 12,892 IGRA tests (95.0%) were negative, 461 (3.4%) were positive and 221 (1.6%) were indeterminate, resulting in a weighted TBI prevalence of 3.2% (95% CI: 2.9–3.5) and weighted positive IGRA prevalence of 3.8% (95% CI: 3.5–4.2) among adults aged 15–64 years in the background population of Denmark. Unweighted TBI prevalence increased with age and birthplace in countries with a TB IR higher than 10/100,000 population. Conclusion: Estimated TBI prevalence is low in Denmark. We estimate that 200,000 persons have TBI and thus are at risk of developing TB. Screening for TBI and preventive treatment, especially in persons born in high TB incidence countries or immunosuppressed, are crucial to reduce the risk of and eliminate TB.Keywords
This publication has 26 references indexed in Scilit:
- The cascade of care in tuberculosis infection screening and management in newly arrived refugees in Aarhus, DenmarkTravel Medicine and Infectious Disease, 2022
- Quantifying the rates of late reactivation tuberculosis: a systematic reviewThe Lancet Infectious Diseases, 2021
- Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settingsNature Medicine, 2020
- Long-term risk of tuberculosis among migrants according to migrant status: a cohort studyInternational Journal of Epidemiology, 2020
- Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseasesJournal of Infection, 2019
- Revisiting the timetable of tuberculosisBMJ, 2018
- Tuberculosis in the elderly: Why inflammation mattersExperimental Gerontology, 2018
- The Danish Civil Registration System as a tool in epidemiologyEuropean Journal of Epidemiology, 2014
- Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis InfectionClinical Microbiology Reviews, 2014
- Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infectionInflammatory Bowel Diseases, 2011